Etiyopatogenez
Özet
Fibromiyalji sendromu (FMS), etiyolojisi ve patogenezi tam olarak aydınlatılamamış, multifaktöriyel bir kronik ağrı bozukluğudur. Hastalığın gelişiminde nöroendokrin ve otonom sinir sistemi düzensizlikleri, genetik varyantlar, psikososyal faktörler ve çevresel stresörler gibi çok sayıda mekanizma rol oynamaktadır. Genetik çalışmalar, SLC64A4 ve TRPV2 gibi genlerin ağrı duyarlılığı üzerindeki etkisini vurgularken, kronik ağrı oluşumu ile genetik faktörler arasında %50'ye varan bir ilişki olduğunu göstermektedir. Patofizyolojide, hipotalamo-hipofizer-adrenal (HPA) aks bozuklukları nedeniyle sirkadiyen kortizol ritminde düzensizlikler ve düşük ACTH yanıtı gözlenmektedir. Ayrıca, beyin omurilik sıvısında serotonin düzeyinin düşük, Substans P seviyesinin ise yüksek olması anormal ağrı algısını ve uyku bozukluklarını tetiklemektedir. Uyku mekanizmasında görülen alfa-delta anomalisi ve proinflamatuvar sitokinlerin (IL-1 beta, IL-6, IL-8, TNF-alfa) salınımı nosisepsiyonu kolaylaştırarak semptomları şiddetlendirmektedir. Depresyon ve posttravmatik stres bozukluğu gibi psikiyatrik durumların yanı sıra kas yapısındaki metabolik değişiklikler de klinik tabloyu karmaşıklaştırmaktadır. Sonuç olarak fibromiyalji; santral sensitivite, hormonal düzensizlikler ve immünolojik süreçlerin bir arada bulunduğu karmaşık bir tablodur.
Fibromyalgia syndrome (FMS) is a complex chronic pain disorder with a multifactorial etiology and pathogenesis that remains fully elucidated. Its pathophysiology involves a combination of neuroendocrine alterations, autonomic nervous system dysfunction, genetic vulnerability, psychological factors, and environmental stressors. Genetic variants, particularly in genes like SLC64A4 and TRPV2, are estimated to have a 50% correlation with chronic pain susceptibility and altered pain thresholds. Neuroendocrine studies highlight dysregulations in the hypothalamic-pituitary-adrenal (HPA) axis, characterized by flattened circadian cortisol curves and blunted ACTH responses. Furthermore, decreased serotonin and elevated Substance P levels in the cerebrospinal fluid contribute significantly to aberrant pain processing and non-restorative sleep. Sleep disturbances, explicitly characterized by the alpha-delta sleep anomaly, alongside elevated proinflammatory cytokines (IL-1 beta, IL-6, IL-8, TNF-alpha), facilitate central sensitization and amplify nociception. Psychological comorbidities, such as depression and post-traumatic stress disorder, alongside localized metabolic alterations in muscle tissue, further complicate the clinical presentation. Consequently, FMS is conceptualized as a multi-system disorder driven by interconnected central sensitivity, hormonal imbalances, and immune-inflammatory mechanisms.
Referanslar
Bradley, Laurence A. "Pathophysiology of fibromyalgia." The American journal of medicine 122.12 (2009): S22-S30.
Siracusa, Rosalba, et al. "Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update." International Journal of Molecular Sciences 22.8 (2021): 3891.
Buskila, Dan. "Genetics of chronic pain states." Best practice & research clinical rheumatology 21.3 (2007): 535-547.
Gür, Ali. "Fibromiyaljide Etiyopatogenez." Turkish Journal of Physical Medicine & Rehabilitation/Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi 54.2 (2008).
Russell, I. Jon, et al. "Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 37.11 (1994): 1593-1601.
Vaerøy, Henning, et al. "Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis." Pain 32.1 (1988): 21-26.
Yunus, Muhammad B. "Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes." Seminars in arthritis and rheumatism. Vol. 36. No. 6. WB Saunders, 2007.
Bennett, Robert M., et al. "Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia." The Journal of rheumatology 24.7 (1997): 1384-1389.
Paul-Savoie, Emilie, et al. "Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments?." The open rheumatology journal 6 (2012): 296.
Okifuji, Akiko, and Dennis C. Turk. "Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome." The Journal of Pain 7.11 (2006): 851-859.
Bagge, E., et al. "Low growth hormone secretion in patients with fibromyalgia--a preliminary report on 10 patients and 10 controls." The Journal of rheumatology 25.1 (1998): 145-148.
Yunus, M. B., F. X. Hussey, and J. C. Aldag. "Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study." The Journal of rheumatology 20.9 (1993): 1557-1560.
Haack, Monika, Elsa Sanchez, and Janet M. Mullington. "Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers." Sleep 30.9 (2007): 1145-1152.
Moldofsky, Harvey. "Sleep and pain." Sleep medicine reviews 5.5 (2001): 385-396.
Okifuji, A. K. I. K. O., DENNIS C. Turk, and JEFFREY J. Sherman. "Evaluation of the relationship between depression and fibromyalgia syndrome: why aren't all patients depressed?." The Journal of rheumatology 27.1 (2000): 212-219.
Sherman, Jeffrey J., Dennis C. Turk, and Akiko Okifuji. "Prevalence and impact of posttraumatic stress disorder-like symptoms on patients with fibromyalgia syndrome." The Clinical journal of pain 16.2 (2000): 127-134.
Bengtsson, Ann, K-G. Henriksson, and JÖRgen Larsson. "Muscle biopsy in primary fibromyalgia: Light-microscopical and histochemical findings." Scandinavian journal of rheumatology 15.1 (1986): 1-6.
Bennett, Robert M., et al. "Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle." Arthritis & Rheumatism 32.4 (1989): 454-460.
